| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/25-1/100 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/2000-1/5000 | Human,Mouse,Rat |
| Aliases | T1; ANT; AAC1; ANT1; PEO2; PEO3; ANT 1; PEOA2; MTDPS12; MTDPS12A |
| WB Predicted band size | 33 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse, Rat |
| Immunogen | Synthetic peptide of human SLC25A4 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于SPARCL1抗体的3篇参考文献的简要总结(基于公开研究整理，具体文献信息可能需要进一步验证)：
1. **文献名称**: "SPARCL1 suppresses metastasis in prostate cancer by inhibiting focal adhesion kinase"
**作者**: Yiu et al.
**摘要**: 研究通过免疫组化和Western blot分析，发现SPARCL1在转移性前列腺癌中表达下调，其抗体检测结果显示SPARCL1通过抑制FAK信号通路减少肿瘤细胞迁移和侵袭。
2. **文献名称**: "SPARCL1 as a prognostic biomarker in glioblastoma: An antibody-based immunohistochemical study"
**作者**: Chen et al.
**摘要**: 使用SPARCL1特异性抗体对胶质母细胞瘤组织进行染色，发现高表达SPARCL1的患者生存期显著延长，提示其可作为预后标志物及潜在治疗靶点。
3. **文献名称**: "SPARCL1 regulates endothelial cell barrier function through interaction with integrin β1"
**作者**: Smith et al.
**摘要**: 通过免疫沉淀和免疫荧光技术，发现SPARCL1抗体阻断实验表明其通过结合整合素β1维持血管内皮屏障完整性，可能在血管炎症中起保护作用。
如需具体文献来源，建议通过PubMed或Google Scholar搜索上述标题关键词获取原文链接。
SPARCL1 (Secreted Protein Acidic and Cysteine-Rich-like 1), also known as Hevin or MAST9. is a member of the SPARC family of matricellular proteins. It is a secreted glycoprotein involved in regulating cell-matrix interactions, tissue remodeling, and cellular adhesion. Structurally, SPARCL1 contains conserved domains typical of SPARC family members, including an N-terminal acidic region and a C-terminal extracellular calcium-binding domain. It plays critical roles in diverse biological processes, such as synaptic organization in the nervous system, angiogenesis, and tumor suppression. Studies highlight its dual role in cancer: it can inhibit tumor progression by modulating cell adhesion and signaling pathways (e.g., TGF-β, Wnt), but may also promote metastasis in certain contexts by facilitating extracellular matrix (ECM) remodeling.
SPARCL1 antibodies are immunological tools designed to detect and quantify SPARCL1 protein expression in research applications. These antibodies are widely used in techniques like Western blotting, immunohistochemistry, and immunofluorescence to study SPARCL1's spatial-temporal expression patterns, particularly in neurological disorders, vascular diseases, and cancer biology. Commercial SPARCL1 antibodies are typically raised against specific epitopes (human or murine) and validated for species reactivity. Recent research explores SPARCL1's potential as a diagnostic or prognostic biomarker, driving demand for high-specificity antibodies. However, challenges remain in distinguishing SPARCL1 from homologous family members (e.g., SPARC/osteonectin) due to sequence similarities, necessitating rigorous validation for experimental accuracy.
×
